Pharvaris/PHVS

$20.27

-7.44%
-
1D1W1MYTD1YMAX

About Pharvaris

Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Ticker

PHVS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Berndt Modig

Employees

82

Headquarters

Leiden, Netherlands

Pharvaris Metrics

BasicAdvanced
$1.18B
Market cap
-
P/E ratio
-$2.69
EPS
-
Beta
-
Dividend rate
$1.18B
$33.00
$7.93
106.88K
27.272
0.011
0.062
-33.51%
-35.62%
-37.83%
-37.81%
2.802
2.884
-11.27%

What the Analysts think about Pharvaris

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
67.59% upside
High $49.53
Low $12.88
$20.27
Current price
$33.97
Average price target

Pharvaris Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€0
-
Net income
€-32.7M
39.15%
Profit margin
0%
-

Pharvaris Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 42.59%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-€0.67
-€0.63
-€0.58
-€0.76
-
Expected
-€0.75
-€0.65
-€0.60
-€0.53
-€0.55
Surprise
-10.08%
-3.06%
-4.11%
42.59%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Pharvaris stock?

Pharvaris (PHVS) has a market cap of $1.18B as of April 15, 2024.

What is the P/E ratio for Pharvaris stock?

The price to earnings (P/E) ratio for Pharvaris (PHVS) stock is 0 as of April 15, 2024.

Does Pharvaris stock pay dividends?

No, Pharvaris (PHVS) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Pharvaris dividend payment date?

Pharvaris (PHVS) stock does not pay dividends to its shareholders.

What is the beta indicator for Pharvaris?

Pharvaris (PHVS) does not currently have a Beta indicator.

What is the Pharvaris stock price target?

The target price for Pharvaris (PHVS) stock is $33.97, which is 67.59% above the current price of $20.27. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Pharvaris stock

Buy or sell Pharvaris stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing